Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Raising Finance During the COVID-19 Crisis (<em>LSX</em>)

Raising Finance During the COVID-19 Crisis (LSX)

Related Content

EMA Issues Positive CHMP Opinions for Biocon’s Denosumab Biosimilars

District of New Jersey Denies Preliminary Injunction in Ustekinumab Breach of Contract Case

EmblemHealth Files Class Action Antitrust Against Alexion Related to Eculizumab

CuraTeQ Biologics’ Trastuzumab biosimilar Receives Positive Opinion in Europe

Update on Regeneron’s Supplemental BLA for EYLEA HD

Regeneron, Mylan, and Biocon Settle in Aflibercept BPCIA Litigation

Washington Becomes First State to Adopt Filing Requirements for HSR-Reportable Transactions Outside of Healthcare

Charting a Conditional Approval Pathway for Rare Disease Drugs – A Top Priority for a Revamped FDA?

Rare Disease Industry Awaits FDA Chief’s New Drug Pathway Plan (Bloomberg Law)

AI in Healthcare: Private Equity’s Next Frontier? (Real Deals)

Kronos Bio To Be Taken Private by Concentra Biosciences

Goodwin Welcomes Leading Life Sciences and Intellectual Property Partner William T. Christiansen II Ph.D.

Goodwin Guides Apnimed in Acquisition of Global Rights to Patents Covering Sulthiame, a Differentiated Carbonic Anhydrase Inhibitor

Goodwin Guides Oak Hill Bio in Exclusive Licensing Agreement with Roche to Obtain Global Rights for a Treatment for Individuals with Angelman Syndrome

Goodwin’s Israel Practice Highly Ranked by Chambers and Israel Desks

SpringWorks Therapeutics To Be Acquired By Merck KGaA, Darmstadt, Germany For $3.9 Billion

Life Sciences

Technology